
The best Bull and Bear pitches based on recency and number of recommendations.
BIOVEST INTERNATIONAL INCORPORATED (OTCBB: BVTI) "Up 3.33% in morning trading"Detailed Quote: http://www.otcpicks.com/quotes/BVTI.phpBiovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for… More
Read the most recent pitches from players about BVTIQ.
Recs
BIOVEST INTERNATIONAL INCORPORATED (OTCBB: BVTI)
"Up 3.33% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BVTI.php
Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ: ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently completing a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.
BVTI News:
November 15 - New Phase III Data Analysis for BiovaxID®, Personalized Lymphoma Vaccine, to Be Presented at ASH Annual Meeting
Biovest International, Inc. (OTC: BVTI) announced that BiovaxID®, Biovest’s personalized lymphoma vaccine, will be featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Monday, December 6th in Orlando, Florida.
Stephen J. Schuster, M.D., Associate Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, will deliver the BiovaxID presentation titled, “Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration in Follicular Lymphoma Patients.”
Recs
Biovest is emerging from bankruptcy. They make individualized vaccines for non hodgkins lymphoma. Their products are in use in Europe and have been granted orphan drug status by the FDA.
A reorganization plan will be announced any day. Accentia (ABPIQ) owns majority interest in Biovest. Accentia is also emerging from BK any day now. They have some other drugs they are working on like Sinunase, but the winner in BiovaxID, the personlized cancer vaccine.
The stock has experience a ridiculous run up since I first blogged about it in April of 2008 when it was .47 cents, but only after a plunge to .10.
This stock experiences wild volatility. The volume is thin. When they make a presentation to doctors or investors the price can fluctuate quite a bit.
Find the members with the highest scoring picks in BVTIQ.
stockjock11 (< 20) Score: +341.33
The Score Leader is the player with the highest score across all their picks in BVTIQ.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
stockjock11 | < 20 | 4/7/2010 |
![]() |
5Y | $1.80 | -98.94% | +242.39% | +341.33 | 0 Comment | |
TMFStockSpam | 27.56 | 11/18/2010 |
![]() |
NS | $1.32 | -98.56% | +237.92% | +336.48 | 1 Comment | |
Scottie31 | 90.78 | 12/3/2010 |
![]() |
5Y | $1.20 | -98.42% | +231.74% | +330.16 | 0 Comment | |
SneakyPete21 | < 20 | 12/6/2010 |
![]() |
5Y | $1.30 | -98.54% | +231.47% | +330.01 | 0 Comment | |
liszewski | 99.97 | 12/7/2010 |
![]() |
5Y | $1.19 | -98.40% | +227.97% | +326.37 | 0 Comment | |
NachOben | 43.43 | 2/16/2011 |
![]() |
3M | $0.72 | -97.36% | +203.48% | +300.84 | 0 Comment | |
FishSRQ | 25.37 | 1/11/2011 |
![]() |
5Y | $0.85 | -97.76% | +218.96% | -316.72 | 0 Comment | |
MTBB | 26.21 | 12/21/2010 |
![]() |
3Y | $0.95 | -97.99% | +225.21% | -323.20 | 0 Comment | |
![]() |
DarkToast | 30.73 | 4/14/2010 |
![]() |
3Y | $1.80 | -98.94% | +237.97% | -336.92 | 2 Comments |
MoTrFinger | < 20 | 5/5/2010 |
![]() |
5Y | $1.67 | -98.86% | +246.09% | -344.95 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.